Current Aspects of Drug Therapy in Philadelphia-positive CML: Correlation of Tumor Burden with Survival

References

• Griffin J. D., Todd R. F., Ritz J., Nadier L. M., Canellos G. P., Rosenthal D., Gallivon M., Beveridge R. P., Weinstein H., Karp D., Schlossman S. F. Differentiation Patterns in the Blastic Phase of Chronic Myeloid Leukemia. Blood 1983; 61: 85–91
   PubMed Web of Science ®Google Scholar
• Thomas E. D., Clift R. A. Indications for Marrow Transplantation in Chronic Myelogenous Leukemia. Blood 1989; 73: 861–864
   PubMed Web of Science ®Google Scholar
• Armitage J. O. Bone Marrow Transplantation. N. Engl. J. Med. 1994; 330: 827–838
   PubMed Web of Science ®Google Scholar
• Beatty P. G., Anasetti C., Hansen J. A., Longton G. M., Sanders J. E., Martin P. J., Mickelson E. M., Choo S. Y., Petersdorf E. W., Pepe M. S., Applebaum F. R., Bearman S. I., Buckner C. D., Clift R. A., Petersen F. B., Singer J., Stewart P. S., Storb R. F., Sullivan K. M., Tesler M. C., Witherspoon R. P., Thomas E. D. Marrow Transplantation From Unrelated Donors for Treatment of Hematologic Malignancies: Effects of Mismatching for One HLA Locus. Blood 1993; 81: 249–253
   PubMed Web of Science ®Google Scholar
• Kernan N. A., Bartsch G., Ash R. C., Beatty P. G., Champlin R., Filipovich A., Gajewski J., Hansen J. A., Henslee-Downey J., McCullough J., McGlave P., Perkins H. A., Phillips G. L., Sanders J., Stroncek D., Thomas E. D., Blume K. G. Analysis of 462 Transplantations from Unrelated Donors Facilitated by the National Marrow Donor Program. New Engl. J. Med., 328: 593–602
   PubMed Web of Science ®Google Scholar
• Haut A., Abbott W. S., Wintrobe M. M., Cartwright G. E. Busulfan in the Treatment of Chronic Myelocytic Leukemia: the Effect of Long Term Intermittent Therapy. Blood 1961; 17: 1–19
   PubMed Web of Science ®Google Scholar
• Galton D. A. G. Chemotherapy of Chronic Myelocytic Leukemia. Semin. Hematol. 1969; 6: 323–343
   PubMed Web of Science ®Google Scholar
• Müller L., Hehlmann R. 24 Jahre Überlebenszeit bei chronisch myeloischer Leukämie. Klin. Wochenschr. 1987; 65: 673–676
   PubMedGoogle Scholar
• Brodsky I., Fuscaldo K. E., Kahn S. B., Conroy J. F. Myeloproliferative Disorders. II. CML: Clonal Evolution and its Role in Management. Leuk. Res. 1979; 3: 379–393
   PubMed Web of Science ®Google Scholar
• Cunningham I., Gee T., Dowling M., Chaganti R., Bailey R., Hopfan S., Bowden L., Turnbull A., Knapper W., Clarkson B. Results of Treatment of Ph1+ Chronic Myelogenous Leukemia with an Intensive Treatment Regimen (L-5 Protocol). Blood 1979; 53: 375–395
   PubMed Web of Science ®Google Scholar
• Goto T., Nishikori M., Arlin Z., Gee T., Kempin S., Burchenal J., Strife A., Wisniewski D., Lambek C., Little C., Jhanwar S., Chaganti R., Clarkson B. Growth Characteristics of Leukemic and Normal Hematopoietic sells in Ph1+ Chronic Myelogenous Leukemia and Effects of Intensive Treatment. Blood 1982; 59: 793–808
   PubMed Web of Science ®Google Scholar
• Sharp J. C., Joyner M. V., Wayne A. W., Kemp J., Crofts M., Birch A. D. J., McArthur G., Lai S., Sterndale H., Williams Y. Karyotypic Conversion in Ph-1-positive Chronic Myeloid Leukemia with Combination Chemotherapy. Lancet 1979; 1: 1370–1372
   PubMed Web of Science ®Google Scholar
• Kantarjian H. M., Vellekoop L., McCredie K. B., Keating M. J., Hester J., Smith T., Barlogie B., Trujillo J., Freireich E. J. Intensive Combination Chemotherapy (ROAP 10) and Splenectomy in the Management of Chronic Myelogenous Leukemia. J. Clin. Oncol. 1985; 3: 192–200
   PubMed Web of Science ®Google Scholar
• Kantarjian H. M., Talpaz M., Kurzrock R., Keating M. J., McCredie K. B., Gutterman J., Freireich E. J. Intensive Combination Chemotherapy and Interferons in the Management of Chronic Myelogenous Leukemia. Acta. haemat. 1987; 78((suppl. 1))70–74
   PubMedGoogle Scholar
• Hehlmann R. Cytostatic Therapy in Chronic Myelogenous Leukemia: Review and Perspectives. Chronic Myelocytic Leukemia and Interferon, D. Huhn, K. P. Hellriegel, N. Niederle. Springer Verlag, Berlin 1988; 102–112
   Google Scholar
• Kennedy B. J. Hydroxyurea Therapy in Chronic Myelogenous Leukemia. Cancer 1972; 29: 1052–1056
   PubMed Web of Science ®Google Scholar
• Bolin R. W., Robinson W. A., Sutherland J., Hamman R. F. Busulfan Versus Hydroxyurea in Long-term Therapy of Chronic Myelogenous Leukemia. Cancer 1982; 50: 1683–1687
   PubMed Web of Science ®Google Scholar
• Rushing D., Goldman A., Gibbs G., Howe R., Kennedy B. J. Hydroxyurea versus Busulfan in the Treatment of Chronic Myelogenous Leukemia. Am. J. Clin. Oncol. (CCT) 1982; 5: 307–313
   PubMed Web of Science ®Google Scholar
• Hehlmann R., Heimpel H., Hasford J., Kolb H. J., Pralle H., Hossfeld D. K., Queiβer W., Löffler H., Heinze B., Georgii A., Wussow Pv., Bartram C. R., Grießhammer M., Bergmann L., Essers U., Falge C., Hochhaus A., Queißer U., Sick C., Meyer P., Schmitz N., Verpoort K., Eimermacher H., Walther F., Westerhausen M., Kleeberg U. R., Heilein A., Käbisch A., Barz C., Zimmermann R., Meuret G., Tichelli A., Berdel W. E., Kanz L., Anger B., TiggesSchmid F. J., Brockhaus W., Zankovich R., Schläfer U., Weißenfels I., Mainzer K., Tobler A., Perker M., Hohnloser J., Messerer D., Thiele J., Buhr T., Ansari H. and the German CML Study Group. (1993) Randomized Comparison of Busulfan and Hydroxyurea in Chronic Myelogenous Leukemia (CML): Prolongation of Survival by Hydroxyurea. Blood, 82: 398–407
   PubMed Web of Science ®Google Scholar
• Talpaz M., McCredie K., Mavligit G. M., Gutterman J. U. Leukocyte Interferon-induced Myeloid Cytoreduction in Chronic Myelogenous Leukemia. Blood 1983; 62: 689–692
   PubMed Web of Science ®Google Scholar
• Talpaz M., Kantarjian H. M., McCredie K., Trujillo J. M., Keating M. J., Gutterman J. U. Hematologic Remission and Cytogenetic Improvement Induced by Recombinant Human Interferon alpha in Chronic Myelogenous Leukemia. N. Engl. J. Med. 1986; 314: 1065–1069
   PubMed Web of Science ®Google Scholar
• Talpaz M., Kantarjian H., Kurzrock R., Trujillo J. M., Gutterman J. U. Interferon Alpha Produces Sustained Cytogenetic Responses in Chronic Myelogenous Leukemia. Ann. Intern. Med. 1991; 114: 532–538
   PubMed Web of Science ®Google Scholar
• Hehlmann R., Heimpel H., Hasford J., Kolb H. J., Pralle H., Hossfeld D. K., Queißer W., Löffler H., Hochhaus A., Heinze B., Georgii A., Bartram C. R., Grießhammer M., Bergmann L., Essers U., Falge C., Queißer U., Meyer P., Schmitz N., Eimermacher H., Walther F., Fett W., Kleeberg U. R., Käbisch A., Nerl C., Zimmermann R., Meuret G., Tichelli A., Kanz L., Tigges F. J., Schmid L., Brockhaus W., Tobler A., Reiter A., Perker M., Emmerich B., Verpoort K., Zankovich R., Wussow P., Prümmer O., Thiele J., Buhr T., Carbonell F., Ansari H., the German CML Study Group. Randomized Comparison of Interferon-alpha with Busulfan and Hydroxyurea in Chronic Myelogenous Leukemia (CML). Blood, 84: 4064–4077
   PubMed Web of Science ®Google Scholar
• Anderson P. K. Conditional Power Calculations as an Aid in Decision whether to Continue a Clinical Trial. Controlled Clin. Trial 1987; 8: 67–74
   PubMedGoogle Scholar
• Simon R., Makuch R. W. A Non-parametric Graphical Representation of the Relationship Between Survival and the Occurence of an Event: Application to Responder Versus Non-responder Bias. Stat. Med. 1984; 3: 35
   PubMed Web of Science ®Google Scholar
• Griesshammer M., Hehlmann R., Hochhaus A., Talpaz M., Tura S., Stryckmans P., Allan N. C., Tanzer J., Kolb H. J., Heimpel H. Interferon in Chronic Myelogenous Leukemia. A Workshop Report. Ann. Hematol. 1993; 67: 101–106
   PubMed Web of Science ®Google Scholar
• The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Interferon alfa-2a as Compared with Conventional Chemotherapy for the Treatment of Chronic Myeloid Leukemia. N. Engl. J. Med. 1994; 330: 820–825
   PubMed Web of Science ®Google Scholar
• Allan N. C., Richards S. M., Shepherd P. C. A. UK Medical Research Council Randomized, Multicentre Trial of Interferon-αn1 for Chronic Myeloid Leukaemia is not Confined to Patients with Cytogenetic Response: Improved Survival Irrespective of Cytogenetic Response. Lancet 1995; 345: 1392–1397
   PubMed Web of Science ®Google Scholar
• Kloke O., Niederle N., Qiu J. Y., Moritz T., Nagel-Hiemke M., Opalka B., Seeber S., Becher R. Impact of Interferon Alpha-induced Cytogenetic Improvement on Survival in Chronic Myelogenous Leukaemia. Brit. J. Haematol. 1993; 83: 399–403
   PubMed Web of Science ®Google Scholar
• Ozer H., George S. L., Schiffer C. A., Rao K., Rao P. N., Wurster-Hill D. H., Arthur D. D., Powell B., Gottlieb A., Peterson B. A., Rai K., Testa J. R., LeBeau M., Tantravahi R., Bloomfield C. D. Prolonged Subcutaneous Administration of Recombinant α 2b Interferon in Patients With Previously Untreated Philadelphia Chromosome-Positive Chronic-Phase Chronic Myelogenous Leukemia: Effect on Remission Duration and Survival: Cancer and Leukemia Group B Study 8583. Blood 1993; 82: 2975–2984
   PubMed Web of Science ®Google Scholar
• Kantarjian H. M., Smith T. L., O'Brien S., Beran M., Pierce S., Talpaz M. Prolonged Survival in Chronic Myelogenous Leukemia Following Cytogenetic Response to Alpha Interferon Therapy. Ann. Intern. Med. 1995; 122: 254–261
   PubMed Web of Science ®Google Scholar
• Sokal J. E., Cox E. B., Baccarani M., Tura S., Gomez G. A., Robertson J. E., Tso C. Y., Braun T. J., Clarkson B. D., Cervantes F., Rozman C., the Italian Cooperative CML Study Group. Prognostic Discrimination in “Good-Risk” Chronic Granulocytic Leukemia. Blood, 63: 789–799
   PubMed Web of Science ®Google Scholar
• Hehlmann R., Heimpel H., Hasford J., the German CML Study Group. Randomized Comparison of Interferon alpha, Hydroxyurea and Busulfan in CML. Blood, 85: 3000–3002
   Web of Science ®Google Scholar
• Mahon F. X., Montastruc M., Faberes C., Reiffers J. Predicting Complete Cytogenetic Response in Chronic Myelogenous Leukemia Patients Treated with Recombinant Interferon α. Blood 1994; 84: 3592–3594
   PubMed Web of Science ®Google Scholar
• Kantarjian H. M., Talpaz M., Keating M. J., Estey E. H., O'Brien S., Beran M., McCredie K. B., Gutterman J., Freireich E. J. Intensive Chemotherapy Induction followed by Interferon-Alpha Maintenance in Patients With Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia. Cancer 1991; 68: 1201–1207
   PubMed Web of Science ®Google Scholar
• Hoyle C., Gray R., Goldman J. Autografting for patients with CML in chronic phase: an update. Brit. J. Haematol. 1994; 86: 76–81
   PubMed Web of Science ®Google Scholar
• Carella A. M., Podesta M., Frassoni F., Raffo M. R., Pollicardo N., Pungolino E., Vimercati R., Sessarego M., Parodi C., Rabitti C., Ferrero R., Benvenuto F., Figari O., Carlier P., Levcasic G., Valbonesi M., Vitale V., Giordano D., Pierluigi D., Nati S., Guerraçio A., Rosso C., Saglio G. Collection of ‘normal’ blood repopulating cells during early hemopoietic recovery after intensive conventional chemotherapy in chronic myelogenous leukemia. Bone Marrow Transplantation 1993; 12: 267–271
   PubMed Web of Science ®Google Scholar
• Carella A. M., Frassoni F., Pollicardo N., Pungolino E., Ferrero R., Vasallo F., Soracco M., Giordano D., Figari O., Benvenuto F., Florio G., Carlier P., Valbonesi M. Philadelphia-chromosome-negative peripheral blood stem cells can be mobilized in the early phase of recovery after a myelosuppressive chemotherapy in Philadelphia-chromosome-positive acute lymphoblastic leukemia. Brit. J. Haematol. 1995; 89: 535–538
   PubMed Web of Science ®Google Scholar
• Simonsson B., öberg G., Killander A., Björeman M., Björkholm M., Gahrton G., Hast R., Turesson I., Udén A. M., Malm C., Vilén L., Wahlin A., Löfvenberg E., Carneskog J., Westin J. Intensive Treatment in Order to Minimize the Ph-Positive Clone in Chronic Myelogenic Leukemia. Stem Cells 1993; 11((suppl 3))73–76
   PubMedGoogle Scholar
• McGlave P. B., De Fabritiis P., Deisseroth A., Goldman J., Barnett M., Reiffers J., Simonsson B., Carella A., Aeppli D. Autologous transplants for chronic myelogenous leukaemia: results from eight transplant groups. Lancet. 1994; 343: 1486–1488
   PubMed Web of Science ®Google Scholar
• Gale R. P., Baccarani M., Horowitz M. M., Zhang M. J. Is the Course of Chronic Myelogenous Leukemia Affected by Bone Marrow Transplantation? An Analysis in Patients Relapsing after Bone Marrow Transplants. Blood 1993; 92(Suppl. 1)167a
   Google Scholar
• Horowitz M. Annual Meeting of the German CML Study Group, Wachenburg/Weinheim, June 23/24, 1995
   Google Scholar